4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BriaCell Therapeutics Corp. (BCT) operates in the Biotechnology industry and is headquartered in West Vancouver, Canada. Its market capitalization is roughly $41 million. In the fiscal year ended 2024-07-31, BCT reported $0M in revenue and ($5M) in net income.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Interactive charts & full statements →
| Income statement | 2024-07-31 | 2023-07-31 | 2022-07-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Operating Income (EBIT) | ($33M) | ($23M) | ($15M) |
| Net Income | ($5M) | ($20M) | ($27M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-04-30 | 2025-01-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($8M) | ($8M) | ($8M) | ($6M) | ($7M) |
| Net Income | ($7M) | ($7M) | ($8M) | ($6M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-07-31 | 2023-07-31 | 2022-07-31 |
|---|---|---|---|
| Total Assets | $6M | $27M | $43M |
| Total Liabilities | $9M | $31M | $32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BCT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms